MicroRNA-126 regulates HypoxiaInducible Factor-1α which inhibited migration, proliferation, and angiogenesis in replicative endothelial senescence by Alique, Matilde et al.
1Scientific RepoRts |          (2019) 9:7381  | https://doi.org/10.1038/s41598-019-43689-3
www.nature.com/scientificreports
MicroRNA-126 regulates Hypoxia-
Inducible Factor-1α which 
inhibited migration, proliferation, 
and angiogenesis in replicative 
endothelial senescence
Matilde Alique 1, Guillermo Bodega  2, Chiara Giannarelli 3,4,5, Julia Carracedo 6,7 & 
Rafael Ramírez 1
Whereas a healthy endothelium maintains physiological vascular functions, endothelial damage 
contributes to the development of cardiovascular diseases. Endothelial senescence is the main 
determinant of endothelial dysfunction and thus of age-related cardiovascular disease. The objective of 
this study is to test the involvement of microRNA-126 and HIF-1α in a model of replicative endothelial 
senescence and the interrelationship between both molecules in this in vitro model. We demonstrated 
that senescent endothelial cells experience impaired tube formation and delayed wound healing. 
Senescent endothelial cells failed to express HIF-1α, and the microvesicles released by these cells failed 
to carry HIF-1α. Of note, HIF-1α protein levels were restored in HIF-1α stabilizer-treated senescent 
endothelial cells. Finally, we show that microRNA-126 was downregulated in senescent endothelial 
cells and microvesicles. With regard to the interplay between microRNA-126 and HIF-1α, transfection 
with a microRNA-126 inhibitor downregulated HIF-1α expression in early passage endothelial cells. 
Moreover, while HIF-1α inhibition reduced tube formation and wound healing closure, microRNA-126 
levels remained unchanged. These data indicate that HIF-1α is a target of miRNA-126 in protective and 
reparative functions, and suggest that their therapeutic modulation could benefit age-related vascular 
disease.
The vascular endothelium, the epithelial layer that lines the inner surface of blood and lymphatic vessels, forms 
a nearly 1-kg organ and consists of approximately 1–6 × 1013 cells. Endothelial cells have important physiologi-
cal functions, and their dysfunction can contribute to several pathological conditions, including cardiovascular 
disease. Endothelial dysfunction contributes to the development of nearly all types of vascular diseases, such as 
hypertension, coronary artery disease, peripheral vascular disease, chronic heart failure, diabetes, and chronic 
kidney failure1–3.
The vascular endothelium has specialized functions. Angiogenesis consists of the sprouting of new capillaries 
from existing vessels to form functional vascular networks in wound healing and response to tissue ischemia 
(e.g., peripheral artery disease and chronic angina) but also contributes to pathological processes (e.g., cancer, 
atherosclerosis) when this response is inappropriate4,5. Endothelial cell migration is known to be an essential 
step in angiogenesis6. Physiological angiogenesis is highly regulated during development and wound repair7, and 
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Figure 1. HUVECs senescence markers. HUVECs develop a senescence phenotype with increasing passage 
number in vitro. The percentage of senescent HUVECs at different passages was determined by senescence-
associated β-galactosidase staining (A) and C12FDG fluorescence staining (B). The data represent means ± SD 
and are expressed as a percentage of total cells and fold induction respectively with respect to control values 
(early passage cells). Early passage endothelial cells, n = 6; senescent endothelial cells (n = 6); 10 random fields/
each; magnification, x100. (C) Cyclin D1 and (D) Lamin B1 representative Western blots in early passage and 
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its dysregulation is associated with various pathological disorders, including age-related macular degeneration, 
rheumatoid arthritis, tumor progression, and metastasis8. The regulation of blood vessel formation is fundamen-
tal to many physiological and pathological processes, and angiogenesis is a major area with regard to developing 
novel therapeutic approaches for diseases, from ischemia to cancer9.
Aging is the primary unmodifiable cardiovascular risk factor. Oxidative stress10, disruption of cell-cell junc-
tions11, dysfunction of endothelial progenitor cells, vascular inflammation or activation of a specific genetic pro-
gram are all processes involved in vascular aging12. Endothelial senescence (ES) has been associated with the 
initiation or progression of cardiovascular diseases (CVD). ES is linked to vascular aging13 or age-related CVD14 
such as vascular calcification15, yet the cellular and molecular mechanisms involved are not fully understood16. 
Several experimental models, such as the Hayflick replicative senescence model17, have been useful in identifying 
the cellular and molecular changes that occur during cellular senescence and aging.
Hypoxia-inducible factor 1 (HIF-1) is an oxygen-dependent heterodimeric (comprising α and β subunits) 
transcriptional activator that is primarily responsible for adapting cells to hypoxic stress18. The target genes of 
HIF-1 regulate angiogenesis, cell proliferation and survival, and glucose and iron metabolism. HIF-1α concen-
trations in healthy, well-oxygenated tissue and cells are tightly regulated by constant protein degradation19. On 
the other hand, protein chaperone heat shock protein 90 (Hsp90)20 binding stabilizes HIF-1α, preventing its deg-
radation21. HIF-1 is suspected to mediate ES, yet no mechanistic evidence supporting these observations exists.
Microvesicles (MVs) are a heterogeneous population of endogenous cell-derived membrane vesicles that are 
released by many cell types (eg, blood circulating and endothelial cells), with a particle diameter of 100–1000 nm 
and are shed into the circulation under physiological (homeostasis)22 and also in pathological conditions, but to 
a greater extent in the latter23. MVs are critical in intercellular communication due to their capacity to transfer 
of their biological content (proteins, lipids, and nucleic acids) between cells24. MVs mediate physiological and 
pathological processes, including coagulation, reticulocyte maturation, and angiogenesis22–24. MVs circulating 
levels are elevated in pathological conditions characterized by endothelial dysfunction2,25.
MicroRNAs (miRNAs) are non-coding endogenous RNAs (approx. 22 nt) that regulate physiological endothe-
lial cell functions (angiogenesis and wound repair) as well as vascular inflammation in response to pathophys-
iologic stimuli26 by targeting specific mRNAs27. MicroRNA-126 (miR-126) is one of the principal regulators 
of developmental angiogenesis26, endothelial proliferation, migration and network vessel formation in vitro28. 
Recent findings suggest that miR-126 secreted by endothelial cells is transferred to vascular smooth muscle cells29, 
possibly carried by MVs released by these cells. However, no studies have examined the mechanistic interactions 
between miR-126 and HIF-1α in the regulation of endothelial cell function or their involvement in ES or thus in 
the initiation and progression of CVD, prompting us to identify the dynamic interplay between HIF-1α and miR-
126, and the role of miR-126 in determining HIF-1α levels.
To test the hypothesis that HIF-1α and miR-126 are involved in ES, we analyzed their expression in endothe-
lial cells using a well-validated and robust model of replicative senescence17. Then, we examined the possible 
mechanistic relationship between miR-126 and HIF-1α and measured HIF-1 and miRNA-126 content in MVs 
that were released from early passage and senescent endothelial cells.
Results
Primary HUVECs with over 96 population doublings display characteristics of senescence. At 
population doubling (PD) level of 20, HUVECs (between passages 2 and 8) showed less than 3% (2.67 ± 1.46%) 
senescence-associated, beta-galactosidase (SA-β-gal)-stained cells (termed early passage endothelial cells in 
Fig. 1A). Sister cultures of these replicating endothelial cells continued to undergo serial passaging until replica-
tive senescence was reached at PD > 96 (between passages 27 and 38). These replicative senescent endothelial 
cells assumed the typical flattened and enlarged morphology, with over 69% (69.36 ± 11.30%) being SA-β-gal-
positive in the monolayer (termed senescent endothelial cells in Fig. 1A).
Senescence was also measured using the fluorogenic substrate C12FDG, which is cleaved by β-galactosidase, 
generating a fluorescent product that is well retained by the cells. Early passage and senescent endothelial cells 
were stained with C12FDG (Fig. 1B) to confirm the results using the traditional SA-β-gal staining protocol (using 
X-gal as the substrate for β-gal). As expected, senescent endothelial cells showed greater C12FDG fluorescence.
To determine the senescent status of endothelial cells, Cyclin D1 and Lamin B1 proteins were measured by 
Western blot. Senescent endothelial cells showed Cyclin D1 upregulation (Fig. 1C) compared with early passage 
endothelial cells, whereas Lamin B1 (Fig. 1D) levels were lower. Thus, these new cellular markers of senescence 
were modulated in our replicative senescence model in HUVECs. To further validate our model, other typical 
markers of senescence (early markers of DNA damage-induced senescence), such as p53 and p16, were tested30,31. 
Senescent HUVECs increased p53 and p16 expression by Western blot (Supplemental Fig. 1). These data confirm 
that new and conventional cellular markers of senescence fluctuate in our HUVEC model.
Senescent HUVECs have altered endothelial function. Endothelial damage is associated with 
impaired wound healing. To measure its effects on the endothelial aging model in vitro, HUVECs migration and 
proliferation were analyzed by the scratch assay. Inhibition of wound healing was observed in senescent HUVECs 
senescent HUVECs pools. Equal protein loading was confirmed probing with β-actin. The graphs present 
densitometric band analysis normalized to β-actin in arbitrary units (AU). The data represent means ± SD and 
are expressed as fold induction with respect to control values (early passage cells). Early passage endothelial cells 
n = 3 pools; senescent endothelial cells. n = 3 pools. *p < 0.05, **p < 0.01 and ***p < 0.001. Early passage vs. 
senescent HUVECs cells. In the figure graphs, the early passage is called young.
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Figure 2. Wound healing in HUVECs monolayers. (A) Representative photomicrographs of early passage and 
senescent HUVECs monolayers 8 hours after wounding. β-galactosidase staining is showed at the final time. 
Note the flattened morphology and positive senescence-associated SA-β-gal staining of the senescent cells. Red 
lines indicate the edge of the wound repopulating cells. Magnification 100x. (B) Time course of changes in the 
size of the remaining wound. The data points represent the % open area means ± SD. Early passage endothelial 
cells, n = 9 in duplicate; senescent endothelial cells, n = 6 in duplicate. *p < 0.05, **p < 0.01 and ***p < 0.001. 
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monolayers compared with early passage HUVECs cell cultures over 8 hours (Fig. 2). Senescent endothelial cell 
migration was suppressed, and such cells had a flattened morphology and were positive for SA-β-gal staining 
at 8 hours (Fig. 2A). Moreover, healing time was measured at different time points over 8 hours and senescent 
endothelial cells were associated with delayed healing (Fig. 2B). These results show that the migration of senescent 
endothelial cells, as measured by wound healing, are inhibited versus early passage endothelial cells.
HUVECs tube formation was measured by angiogenesis assay to determine whether senescent endothelial 
cells maintained their function, in which senescent endothelial cells significantly decreased angiogenesis (Fig. 2). 
Early passage endothelial cells enhanced tube formation compared with senescent endothelial cells at 6 hours 
(Fig. 2C–E). We also measured the total segment length, total tube length, and the number of nodes—which all 
declined significantly in senescent cells versus early passage HUVECs (Fig. 2F–H). Thus, these changes observed 
during angiogenesis in senescent endothelial cells appear to be associated with aging.
HIF-1α and Hsp90 expression is lower in senescent endothelial cells and microvesicles. HIF-1α 
mRNA and protein levels were examined in both early passage and senescent HUVECs to determine the mecha-
nism of endothelial dysfunction. As shown in Fig. 3A, HIF-1α mRNA was significantly downregulated in senes-
cent versus early passage endothelial cells. Further, HIF-1α protein content was significantly lower in senescent 
HUVECs (Fig. 3B).
Based on the relationship between heat shock protein 90 (Hsp90) and HIF-1α, Hsp90 was evaluated in early 
passage and senescent endothelial cells by Western blot to test the possibility that the modulation of HIF-1α in 
senescent endothelial cells is associated with Hsp90 changes. Paralleling the disappearance of HIF-1α protein in 
senescent endothelial cells, Hsp90 protein declined significantly in senescent HUVECs (Fig. 3C).
Next, we analyzed HIF-1α levels in MVs that were released from endothelial cells. The results showed that 
early passage HUVECs-secreted MVs contained significantly more HIF-1α than their senescent counterparts 
(Fig. 3D). Notably, there were no changes in Hsp90 protein between early passage and senescent MVs (Fig. 3E).
These data clearly demonstrate that replicative endothelial senescence correlates with the loss of HIF-1α in 
endothelial cells and the MVs that they discharge. Furthermore, Hsp90 expression was significantly downregulated 
in senescent endothelial cells, implicating it in the disappearance of HIF-1α. On the other hand, there was no 
change in Hsp90 expression in MVs suggesting that Hsp90 may play a role in the mechanism for MVs loading32.
Deferoxamine mesylate recovers HIF-1α levels in senescent endothelial cells. To determine 
whether the synthesis or degradation of HIF-1α protein in senescent HUVECs is altered, senescent endothelial 
cells were treated with deferoxamine mesylate (DFO), an agent that stabilizes HIF-1α (Fig. 4). HIF-1α mRNA 
fell significantly in senescent endothelial cells that were treated with DFO (Fig. 4A), but the HIF-1α losing was 
reversed by DFO treatment (Fig. 4B,C). This finding suggests that HIF-1α is degraded rapidly in control senes-
cent endothelial cells, an effect that is blunted by the stabilizing effect of DFO and consequent accumulation 
of HIF-1α in senescent endothelial cells, whereas HIF-1α is degraded rapidly in control senescent endothelial 
cells. Notably, the accumulation of HIF-1α in DFO-treated senescent HUVECs lowered HIF-1α mRNA levels, 
perhaps due to a resulting negative feedback mechanism at the transcriptional level through high HIF-1α protein 
levels. DFO treatment did not alter the Hsp90 content in senescent HUVECs (Fig. 4D,E). These data suggest that 
higher HIF-1α protein degradation causes the disappearance of HIF-1α protein in senescent endothelial cells 
independently of Hsp90 protein levels.
We also examined endothelial function in DFO-administered senescent HUVECs by wound-healing assay 
after up to 8 hours of treatment. As a result, the migration rate of DFO-treated senescent HUVECs was unchanged 
compared with control senescent HUVECs, suggesting an HIF-1α independent effect (Fig. 5).
microRNA-126 is decreased in senescent endothelial cells. MiR-126 is essential for endothelial cell 
signaling and promotes migration, proliferation, and angiogenesis. miR-126 was measured by qPCR in early 
passage and senescent HUVECs and MVs. Basal miR-126-5p strand expression was significantly lower compared 
with miR-126-3p strand in both, early passage and senescent endothelial cells (Fig. 6A). These data are concordant 
with previous observations that miR-126-5p is less abundant than miR-126-3p in the resting endothelium26. The 
individual analysis of these transcripts showed lower levels of miR-126-3p and miR-126-5p in senescent vs. early 
passage endothelial cells (Fig. 6B,C). Similarly, senescent HUVECs-secreted MVs contained less miR-126-3p and 
miR-126-5p (Fig. 6D,E). These data imply that replicative endothelial senescence is associated with a decrease in 
miR-126-3p and miR-126-5p in senescent HUVECs and MVs from such cultures.
Effect of HIF-1α inhibition on early passage endothelial cells. We performed functional assays in 
early passage HUVECs to determine the function of HIF-1α in endothelial damage. Early passage endothelial 
Early passage vs. senescent HUVECs cells at the same time. Endothelial tube formation in HUVECs. The 
spontaneous formation of capillary-like structures by HUVEC on Matrigel was used to assess angiogenic 
potential. (C) Light microscope pictures and (D,E) fluorescent microscopy (for HUVECs treated with calcein 
AM) photomicrographs of early passage and senescent HUVECs seeded on Matrigel-coated wells after 6 h. 
Early passage HUVECs migrated to form connected tubular networks; senescent HUVECs significantly 
attenuated network formation. (F–H) Total segment length, total tube length and the number of nodes were 
quantitated from photographs of early passage and senescent HUVECs after 6 hours. (C and D: Magnification: 
100x; E: Magnification: 40x). Data are expressed as means ± SD. Early passage endothelial cells, n = 10 in 
triplicate; senescent endothelial cells, n = 6 in quadruple. *p < 0.05, **p < 0.01, Early passage vs. senescent 
HUVECs. In the figure graphs, the early passage is called young.
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Figure 3. HIF-1α mRNA, and HIF-1α and Hsp90 protein levels in HUVECs. (A) qPCR analysis of HIF-1α 
mRNA levels in early passage and senescent HUVECs pools using the ΔCt method; HPRT1 mRNA was 
used for normalization. Early passage endothelial cells, n = 3 pools; senescent endothelial cells, n = 3 pools. 
*p < 0.05. (B,C) Representative HIF-1α and Hsp90 western blot of early passage and senescent HUVECs 
pools. Equal protein loading was confirmed probing with GAPDH. The graphs present densitometric band 
analysis normalized to GAPDH in arbitrary units (AU). Early passage endothelial cells, n = 3 pools; senescent 
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cells were treated with increasing doses of YC-1 (Abcam), a pharmacological inhibitor of HIF-1α, and examined 
by Western blot. YC-1 treatment for 16 hours dose-dependently downregulated HIF-1α protein, which was slight 
at 30 µM YC-1 (Fig. 7A) in early passage HUVECs. At 100 µM, YC-1 was slightly toxic and induced cell death33 
(cytotoxicity was assessed using Trypan blue in early passage HUVECs; data not shown). YC-1 had no effect on 
Hsp90 (Fig. 7B).
Next, the wound-healing assay was performed with early passage HUVECs that were given increasing doses 
of YC-1 for up to 8 hours. The migration rate of early passage HUVECs treated with YC-1 (0–100 µM) was signif-
icantly lower compared with control HUVECs (Fig. 8A,B).
Finally, early passage endothelial cells were treated with increasing concentrations of YC-1 and analyzed 
by angiogenesis assay (Fig. 8C–F). Images of YC-1-treated endothelial cells at 6 hours showed decreased 
in tube formation vs. control. Further, total segment length, total tube length, and the number of nodes fell 
dose-dependently. Collectively, our results demonstrate that the inhibition of HIF-1α by YC-1 impedes cell 
migration and tube formation in HUVECs.
To test the possibility that HIF-1α modulates miR-126 levels in endothelial cells and thus HUVECs migration 
and angiogenesis, we quantified miR-126-3p and miR-126-5p transcripts in HUVECs that were treated with YC-1 
for 16 hours. No significant difference in miR-126-3p or miR-126-5p levels was observed (Supplemental Fig. 2). 
Consequently, HIF-1α-mediated changes in migration and angiogenesis are independent of miR-126 levels.
Inhibition of microRNA-126 downregulate HIF-1α expression protein in endothelial cells. To 
demonstrate the direct role of miR-126 in the HIF-1α pathway in the homeostasis maintaining in endothelial 
cells, early passage HUVECs were transfected with microRNA inhibitors (antimiRs), miR-126-3p, miR-126-5p or 
both strands, miR-126-3p plus miR-126-5p, or its corresponding anti-miR negative control (NC) inhibitors. We 
show that an endothelial cell-restricted miR-126-3p or miR-126-5p for 72 hours decreased HIF-1α protein com-
pared to the corresponding anti-miR NC inhibitor (Fig. 9). Interestingly, when cells were transfected with both 
sequences of miR-126-3p plus miR-126-5p inhibitors during 72 hours, the HIF-1α protein was also decreased vs. 
the anti-miR NC inhibitor controls. Noteworthy no additive effect was seen as the reduction was similar to that of 
the individual miR-126 inhibitor, 3p strand and 5p strand as well as both strands together (Fig. 9A,B). No change 
of Hsp90 protein in early passage endothelial cells transfected with antimiRs was seen (Fig. 9C,D). These results 
indicate that manipulating the expression of miR-126 in early passage endothelial cells in vitro affected HIF-1α 
protein decreasing its constitutive expression. On the other hand, Hsp90 levels are maintained unalterable sug-
gesting that Hsp90 plays no role in HIF-1α degradation mediated by miR-126.
Discussion
Cell senescence is defined as a type of status characterized by the irreversible arrest of cell proliferation and is 
considered the main contributor to aging and aging-related disease30. In general, the senescent phenotype is dis-
tinguished by the upregulation and secretion of growth factors, extracellular matrix-degrading proteins, and proin-
flammatory cytokines—constituting the senescence-associated secretory phenotype (SASP)34—and decreased 
the ability to migrate35. At the cellular and molecular levels, telomere shortening, genomic and epigenomic 
damage, unbalanced mitogenic signals, and activation of tumor suppressor proteins have been related to cellular 
senescence30. Molecules that are involved in cellular senescence participate in cell cycle control and DNA repair36 
have been used as biomarkers of senescent cells in vitro and in vivo, including the upregulation of SA-β-gal, p16, 
and DcR230 or p21 and Cyclin D137 and the loss of Lamin B138. However, many common cellular markers of 
senescence are considered not sufficiently robust to reliably identify the number of senescent cells when present at 
low frequencies39. To avoid this distortion, we also used SA-β-gal, Cyclin D1, and Lamin B1 as senescent markers. 
Our data provide the first evidence that Lamin B1 and Cyclin D1—recently described11,37,38 as robust markers of 
senescence—are regulated in a replicative senescence HUVECs model.
In addition to the general changes that are associated with cell senescence described above, many cell 
type-specific changes have been reported. In this regard, our data provide the first evidence that the lack of HIF-1α 
is key in the senescence of human endothelial cells. Thereby, the senescence of vascular endothelium has been 
related to vascular aging13 and age-related vascular diseases14, and several mechanisms have been proposed to 
mediate this age-dependent endothelial dysfunction16. Decreased e-NOS expression40, redistribution of the splic-
ing factor SRSF141, endothelial progenitor cell dysfunction42, oxidative stress43, and disruption of cell junctions11  
are all specific mechanisms of endothelial cell senescence. Besides, our results add a new mechanism in the 
age-mediated endothelial damage where HIF-1α plays a role in senescent endothelial cells.
There are little data on the relationship between senescence and HIF-1α. Hypoxia protects cells from 
oncogene-induced senescence through the downregulation of senescence markers, and HIF-1α is directly 
involved in the downregulation of p53 and p21 in fibroblasts44. Also, HIF-1α attenuates or delays premature 
cellular senescence, and the loss of HIF-1α induces premature senescence in fibroblasts45. Recent evidence also 
suggests that increases in HIF-1α due to hypoxic preconditioning inhibit endothelial progenitor cell senescence46. 
Consistent with these results, our findings have revealed the disappearance of HIF-1α in a replicative senescence 
endothelial cells, n = 3 pools. Early passage vs. senescent HUVECs. HIF-1α and Hsp90 protein levels of 
MVs released by HUVECs. (D) Representative HIF-1α and (E) Hsp90 western blot of early passage and 
senescent MVs pools. Equal protein loading was confirmed probing with Ponceau red staining. The graphs 
present densitometric band analysis normalized to Ponceau red staining in arbitrary units (AU). Early passage 
endothelial MVs, n = 3 pools; senescent endothelial MVs, n = 3 pools. The data represent means ± SD. 
***p < 0.001. Early passage vs. senescent. In the figure graphs, the early passage is called young.
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model of human endothelial cells. Similar to previous observations that senescent cells are unable to initiate cell 
division or participate in tissue regeneration and wound healing47, our results show that senescent endothelial 
cells lose the capacity to undergo tube formation and participate in wound repair. Thus, the loss of standard func-
tions that characterize senescent endothelial cells might be attributed to the disappearance of HIF-1α—we found 
that treatment of early passage HUVECs with an HIF-1α inhibitor significantly impaired their function, resem-
bling a senescent phenotype. HIF-1α modulates physiological and pathological wound repair47 and mediates 
Figure 4. DFO effect on HIF-1α protein in senescent HUVECs. (A) qPCR analysis of HIF-1α mRNA in control 
and DFO-treated senescent HUVECs using the ΔCt method; HPRT1 mRNA was used for normalization. (B) 
Representative HIF-1α and (D) Hsp90 western blots in control and DFO-treated (100 µM, 8 hours) senescent 
HUVECs. Equal protein loading was confirmed probing with GAPDH. (C,E) The graphs present densitometric 
band analysis normalized to GAPDH in arbitrary units (AU). The data represent means ± SD. Control vs. DFO-
treated senescent HUVECs cells. ***p < 0.001 n = 4.
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angiogenesis48. We speculate that the loss of HIF-1α from senescent endothelial cells is critical in endothelial 
homeostasis and thus in aging-associated diseases, such as endothelial dysfunction and vascular disease. Future 
studies should examine the mechanism resulting in lack of HIF-1α during cellular senescence.
MVs that are shed from senescent endothelial cells lack HIF-1α; however, those from early passage endothe-
lial cells contain HIF-1α. MVs can be released from nearly all types of cells, and the proteins and miRNAs that 
they carry have potential diagnostic and therapeutic value24,49. This ability to harbor and transfer biological 
information renders MVs an essential route of intracellular communication and could serve as a biomarker49. 
Consequently, HIF-1α-containing MVs from early passage HUVECs could function as an essential signaling 
mechanism that maintains normal endothelial function and vascular homeostasis. In contrast, the absence 
of HIF-1α in senescent MVs suggests that this phenomenon may aggravate the dysfunction of the senescent 
endothelium.
Hsp90 is a chaperone involved in the activation and stabilization of many proteins avoiding proteasomal 
degradation. Thus, we hypothesized that Hsp90 would establish HIF-1α ubiquitination and subsequently degra-
dation via proteasome though Hsp90/HIF-1α complex in early passage and senescent HUVECs. Several client 
proteins of Hsp90 have been identified, most of which are related to signal transduction, cell cycle progression, 
and transcriptional regulation50. Hsp90 is essential in the activation and stabilization of HIF-1α in hypoxia in 
a cell line of human microvascular endothelial20. In fact, Hsp90 inhibitors dissociate Hsp90 from HIF-1α and 
induce the degradation of HIF-1α51. Vascular aging increases ROS in endothelial cells and senescent HUVECs52, 
and ROS-induced Hsp90 cleavage requires iron explaining the low Hsp90 levels that we observed in senes-
cent endothelial cells and the effects of DFO. DFO is an iron chelator and can thus halt ROS-induced Hsp90 
cleavage-also, one of the effects of DFO is to maintain Hsp90 levels in senescent endothelial cells (Fig. 4). To 
elucidate the role of Hsp90 in HIF-1α degradation furthers experiments should be carried out. Moreover, the 
possibility of a direct effect of DFO on the enzymes that participate in HIF-1α metabolism should not be dis-
missed, because iron chelators inhibit hydroxylase activity in HIF-1α degradation53. DFO also sustained HIF-1α 
levels in senescent HUVECs, but this finding could be explained by the well-known stabilizing effect of Hsp90 
on HIF-1α. The translation of Hsp90 is downregulated for specific iron chelators—opposite to our observa-
tions—but this effect has not been demonstrated for DFO54. It is unknown whether HIF-1α degradation depends 
on O2/VHL (von Hippel Lindau), and the disruption of Hsp90 promotes HIF-1α degradation through an O2/
VHL-independent pathway51, which might be the mechanism of degradation in our senescent HUVECs (e.g., 
Hsp90-regulated and O2/VHL-independent) because our cells were not grown under hypoxic conditions. Hsp90 
content becomes significantly lower in senescent HUVECs but does not change in senescent MVs, possible due 
to the incorporation of other client proteins of Hsp90 into MVs. Moreover, another reason why HIF-1α protein 
levels are abolished in senescent endothelial cells may be the higher rate of protein degradation given that DFO (a 
HIF-1α stabilizer) treatment in senescent HUVECs accumulates HIF-1α protein. Accordingly, HIF-1α protein 
half-life in senescent endothelial cells is shorter than in early passage endothelial cells. This result confirms the 
important role that the transcription factor HIF-1α plays in physiological and the pathophysiological conditions 
as an essential mediator of oxygen homeostasis55,56.
Figure 5. DFO effect on wound healing in senescent HUVECs. (A) Representative photomicrographs of 
senescent and DFO-treated senescent HUVECs cells 8 hours after wounding. Red lines indicate the edge of the 
wound repopulating cells. Magnification 100x. (B) Time course of changes in the size of the remaining wound. 
The data points represent the % open area means ± SD. n = 4 in duplicate.
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DFO, which maintains HIF-1α protein levels in treated cells, has no effect on the scratch assay of senes-
cent HUVECs. This result might be attributed to the advanced state of senescence in our model versus other 
paradigms. The rate of PD in HUVECs in our senescent model was 97 (PD > 96; passaged 27–38 times) com-
pared with the current knowledge on replicative senescence in endothelial cells that reported rates of PD > 44 in 
endothelial cells (passage 13)54,57, PD between 49–50 (26 passages and onwards, late senescent HUVECs)58, and 
Figure 6. MiR-126 in early passage and senescent HUVECs and MVs. QPCR analysis of miR-126-3p and miR-
126-5p was performed in early passage and senescent HUVECs pools (A,B,C) and MVs (D,E) using the ΔCt 
method; U6 snRNA was used for normalization in HUVECs. MVs were normalized to a spike in (miR39-3p) 
levels. (A) miR-126-5p expression was lower than miR-126-3p expression in early passage and senescent 
HUVECs using early passage HUVECs miR-126-3p levels as a control. ***p < 0.001, miR-126-5p vs miR-
126-3p in early passage HUVECs. (B) miR-126-3p and (C) miR-126-5p expression was diminished in senescent 
HUVECs versus early passage HUVECs. (D) miR-126-3p and (E) miR-126-5p expression were diminished in 
senescent MVs compared with early passage MVs. Early passage endothelial HUVECs and MVs, n = 3 pools; 
senescent endothelial HUVECs and MVs, n = 3 pools. The data represent means ± SD. *p < 0.05, **p < 0.01 
and ***p < 0.001. Early passage vs. senescent HUVECs or MVs. In the figure graphs, the early passage is called 
young.
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PD approximately 4559,60. Thus, the senescent endothelial state was irreversible, and DFO could not have affected 
the migration or proliferation (endothelial function) of senescent endothelial cells. Moreover, other mediators 
may act in the normal function of the endothelial cells.
Our results reveal that the miR-126 levels in endothelial cells were associated with aging, where the level of 
miR-126 was higher in early passage endothelial cells and early passage endothelial-secreted MVs than in senes-
cent HUVEC and senescent HUVECs-secreted MVs. Regarding this data, miR-126 is highly expressed in vascu-
larized tissues, endothelial cells, and hematopoietic cells61 and is considered a prototypical endothelial-specific 
miRNA because miR-126 is the most highly enriched microRNA in endothelial cells62. Notably, the chief function 
of miR-126 is to regulate angiogenesis and vascular integrity and, therefore, and its expression plays a very impor-
tant role in the endothelial homeostasis26,63. In addition, miR-126 is involved in vessel maturation and is believed 
to be atheroprotective28. Lower miR-126 levels are associated with increased inflammatory mediators64, and miR-
126 is are downregulated in senescent human aortic endothelial cells64. In support of these findings, we also 
observed decreases in miR-126-3p and miR-126-5p levels in senescent HUVECs, which experienced a loss in 
function, as evidenced by the significant reduction in senescent HUVECs angiogenesis, proliferation, and migra-
tion (wound healing). The levels of the miR-126-5p strand were higher compared with the miR-126-3p strand in 
early passage and senescent HUVECs. Both mature miR-126 strands are critical in angiogenesis. A recent study 
showed that silencing of miR-126-3p, but not miR-126-5p, suppresses angiogenesis29. The decreases in miR-126 
expression strands, miR-126-3p and miR-126-5p, in MVs from senescent HUVECs are similar, suggesting para-
crine signaling between nearby cells.
Many studies in recent years have highlighted the possibility of a link between HIF-1α and miR-126. 
Thus, we study their possible interaction in the development of endothelial senescence—the effect of HIF-1α 
on microRNA-126 and also the role of miR-126 in the HIF-1α pathway in endothelial cells. In a recent work, 
miR-126 emerged as a new regulator in hypoxia and reperfusion65. Moreover, some researches show that under 
hypoxia conditions, VEGFA-A (a key factor in angiogenesis initiation) is regulated in endothelial cells and there-
fore, also miR-126, described as a direct VEGFA-A target66. Indeed, miR-126 plays a critical role in the regulation 
of CXCL12/CXCR4 pathway by inhibiting the axis in quiescent endothelial cells and HIF1α-dependent activation 
of this pathway in vascular injury and hypoxia67. In addition, it has been described changes in the expression 
levels of some miRNAs between them, miR-126, that stimulate Akt activation during hypoxia68. Additionally, 
the phosphatidylinositol 3 kinase (PI3K) is the activator of the Akt pathway and is targeted by miR-12669. Hence, 
the observed hypoxic deregulation of miR-126 contributes to increased VEGF expression and Akt activation70. 
Results reported that endothelial cells (HUVECs) under hyperglycemic conditions undergoing senescence and 
miR-126 levels are modified71. According to all the studies above mentioned, our work was focused in the inter-
action miR-126 and HIF-1α. In this regard, there were no changes in miR-126 levels in endothelial cells treated 
with HIF-1α inhibitor. However, the inhibition of miR-126 strands, individually (3p or 5p) or together (3p plus 
Figure 7. Effect of YC-1 on HIF-1α and Hsp90 proteins in early passage HUVECs. Representative (A) 
HIF-1α and (B) Hsp90 protein western blots in early passage HUVECs treated with different doses of YC-1. 
Equal protein loading was confirmed probing with GAPDH. The graphs present densitometric band analysis 
normalized to GAPDH in arbitrary units (AU). The data represent means ± SD. n = 4. YC-1 treated vs. Control 
***p < 0.001.
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Figure 8. Effect of YC-1 in a scratch assay. (A) Representative photomicrographs of cell monolayers 8 hours 
after wounding. Red lines indicate the edge of the wound repopulating cells. Magnification 100x. (B) Time 
course of changes in the size of the remaining wound. The data points represent the % open area means ± SD. 
Control: n = 9 in duplicate; YC-1 30, 50 and 100 µM: n = 4 in duplicate; YC-1 treated vs. Control at the 
same time. *p < 0.05, **p < 0.01 and ***p < 0.001. (C) Effect of YC-1 on tube formation in HUVECs. 
Light microscope pictures of HUVECs seeded on Matrigel-coated wells and treated with different YC-1 
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5p), decrease constitutive HIF-1α protein levels, suggesting that miR-126 is upstream in the relationship between 
HIF-1α and miR-126 in endothelial cells. Specifically, we found that the regulation of endothelial functions is 
through by miR-126/HIF-1α pathway, suggesting that miR-126 modulate HIF-1α protein levels as a mechanism 
in the maintenance of homeostasis in the vascular environment. Beside the antimiRs effect on HIF-1α protein 
expression, Hsp90 levels are maintained unalterable in early passage cells transfected with miR-126 inhibitors 
suggesting as aforementioned that is possible the involvement of others proteins in the HIF-1α protein degrada-
tion/stability via miR-126.
In summary, our work demonstrates that HIF-1α is required to extend the replicative life span and implicated 
in the maintenance of the protective and repair functions of endothelial cells. Moreover, that miR-126 downregu-
lated in senescent endothelial cells supports that miR-126 is an essential signaling that promotes normal endothe-
lial function. HIF-1α and miR-126 disappear and decrease, respectively, in MVs from senescent endothelial cells, 
implicating them as positive regulators between cells. HIF-1α inhibition does not affect miR-126 levels, whereas 
the inhibition of miR-126 diminishes HIF-1α protein. Thus, the miR-126/HIF-1α pathway plays a role in the 
mechanisms by which endothelial function is regulated. These findings identify a new mechanism involved in 
replicative endothelial senescence (Fig. 10). Further in vivo experimental models are warranted to check the role 
of miR-126 in the regulation of HIF and test the potential of molecularly targeting this mechanism for therapeutic 
purposes.
Methods
HUVECs cell cultures. Human umbilical vein endothelial cells (HUVECs; CC-2517, lot number 323352 
Lonza) were purchased as pooled primary cells frozen at passage 1 in a cryopreservation medium containing 
endothelial growth medium (EGM) with 10% heat-inactivated foetal bovine serum (FBS) (Sigma). Cultures 
were maintained at 37 °C in a 5% CO2 atmosphere at 95% humidity in EGM consisting of endothelial basal 
media (EBM; Lonza CC-3121) supplemented with a growth bullet kit (Lonza, CC-4133) containing Bovine Brain 
Extract, ascorbic acid, hydrocortisone, epidermal growth factor, gentamicin/amphotericin-B and supplemented 
with 10% heat-inactivated FBS. All the experiments were carried out in normoxia conditions (∼20% O2)56.
First-passage cryopreserved HUVECs were grown and serially passaged until they reached senescence, 
as described72 (the replicative senescence model) previously. The rate of population doubling (PD) occurring 
between passages was calculated using the formula PD = [ln {number of cells harvested} − ln {number of cells 
seeded})/ln2]. Cells studied within 2–8 passages (early passage; PD < 20) were regarded as early passage endothe-
lial cells, whereas those passaged 27–38 times (PD > 96) were regarded as senescent endothelial cells.
Cytotoxicity assay. Early passage endothelial cells seeded in 6-well plate (105 cells/well) with complete 
endothelial growth medium (EGM supplemented with growth bullet kit and 5% heat-inactivated FBS) and 
treated with YC-1 (0–100 µM) during 8 hours. Later, early passage HUVECs were trypsinized, washed twice with 
PBS and viability was measured using 0.4% Trypan blue staining (from Countess™ Cell Counting Chamber 
Slides kit; ThermoFisher Scientific). Trypan blue exclusion was measured using a hemocytometer (Countess™ 
Automated Cell Counter; ThermoFisher Scientific) and the percentage of viable cells was determined.
Isolation and characterization of microvesicles (MVs). To MVs isolation, early passage and senescent 
HUVEC-derived (isolated from the culture medium) MVs were isolated and pooled. Briefly, cell culture superna-
tants were centrifuged using serial centrifugations (15 min at 3000 rpm to remove cells and cellular debris, 30 min 
at 14000 rpm to concentrate the MVs in Eppendorf centrifuges) based on International Society on Thrombosis 
and Haemostasis73.
MVs from HUVEC cultures were characterized following ISEV guidelines74, using confocal microscopy 
analysis for size control, flow cytometry for the quantification and analysis of membrane markers, and mass 
spectrometry for the detection of protein markers. Confocal microscopy showed MVs to range in size from 0.3 
to 1.2 μm. An equal amount of pooled MVs from early and senescent endothelial cells were characterized in 
term of size using Beckman Coulter Cytomic FC 500 flow cytometer running CXP software. MVs were under-
stood to be those events gated with a size from the side scatter (SSC) vs. forward scatter (FSC) dot-plot pro-
duced in a standardization experiment using the SPHERO™ Flow Cytometry Nano Fluorescent Size Standard 
Kit (Spherotech). The latter has size-calibrated fluorescent beads ranging from 0.1–1.9 μm in diameter. Events 
below 0.2 μm were excluded in order to distinguish true events from the background adequately; events >1.2 
μm were excluded to prevent possible confusions with apoptotic bodies. Moreover, MVs from HUVEC culture 
medium were characterized regarding their protein profile as follow. Double-fluorescent labeling was performed 
to confirm the protein profile of the MVs from HUVECs. This characterization was done by incubating endothe-
lial MVs with fluorescein isothiocyanate-conjugated (FITC) labeled monoclonal anti-CD31 (BD Pharmingen) 
and phycoerythrin-annexin A5 (BD Pharmingen), together in annexin A5-biding buffer (10 mM HEPES, 7.4 pH, 
140 mM NaCl, 2.5 mM CaCl2). Isotype negative controls were also prepared. As a control for the annexin A5 labe-
ling, a sample with fluorescein-conjugated annexin A5 using a CaCl2-free solution was established. To confirm 
concentrations for 6 h. Two representative series of images of endothelial tube structures were shown. Control 
HUVECs migrated to form connected tubular networks. YC-1-treated HUVECs significantly attenuated 
network formation. (D–F) Quantitative analysis of the total segment length, total tube length and the number 
of nodes were performed from photographs. Magnification: 100x. Data are expressed as means ± SD. Control 
cells, n = 10 in triplicate; YC-1 treated cells, n = 4 in triplicate. YC-1 treated vs. Control. *p < 0.05, **p < 0.01 
and ***p < 0.001.
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the exclusion of apoptotic bodies in MVs isolations, the DNA content of the HUVEC-derived MVs was deter-
mined by incubating them with acridine orange (Invitrogen) to a final concentration of 20 mM.
Mass spectrometry analysis was performed as previously described75, and showed the presence of different 
proteins that in the ISEV guidelines are suggested as markers for the four categories of proteins that are rec-
ommended should be checked: tetraspanin and lactadherin (category 1), annexins and syntenin (category 2), 
cytochrome c and HSP90B1 (category 3), and fibronectin, collagen α and MMP14 (category 4). Finally, MVs were 
frozen and stored at −20 °C until use.
Analysis of senescence-associated β-galactosidase (SA-β-gal) activity. SA-β-gal staining was per-
formed using the Senescence-Galactosidase Staining Kit (MBL International Corporation, Catalog #JM-K320-
250) according to the manufacturer’s protocol. In brief, endothelial cells at different passages were plated in a 
12-well plate (6 × 104/well) and analyzed when they reached confluency. The cells were washed with PBS and 
Figure 9. Effect of miR-126 inhibition on HIF-1α and Hsp90 protein levels in early passage HUVECs. (A) 
Representative HIF-1α western blot in early passage HUVECs transfected with negative control (NC) inhibitor, 
miR-126-3p strand, miR-126-5p strand or both sequence inhibitors, miR-126-3p plus miR-126-5p for 72 hours. 
Equal protein loading was confirmed probing with GAPDH. (B) The graphs present densitometric band 
analysis normalized to GAPDH in arbitrary units (AU). The data represent means ± SD. n = 3.Control vs. miR-
126-transfected early passage HUVECs cells. *p < 0.05 and **p < 0.01. (C) Representative Hsp90 western blot 
in early passage HUVECs transfected with negative control (NC) inhibitor, miR-126-3p strand, miR-126-5p 
strand or both sequence inhibitors, miR-126-3p plus miR-126-5p for 72 hours. Equal protein loading was 
confirmed probing with GAPDH. (D) The graphs present densitometric band analysis normalized to GAPDH 
in arbitrary units (AU). The data represent means ± SD. n = 3.
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fixed in fixing solution for 12 min at room temperature. Next, they have washed once again in PBS to remove 
the fixing solution and incubated in freshly prepared SA-β-gal at 37 °C for 16 h without CO2. Afterward, SA-β- 
gal-positive cells (senescent cells) were identified as blue-stained cells under standard light microscopy. The num-
ber of positive cells with blue color was counted and normalized to the number of total cells in the same field. 
The percentage of SA-β-gal-positive cells was counted in 10 randomly selected microscopic fields (magnification 
100x; 400–600 cells).
SA-β-gal activity was also measured by fluorescence microscopy. After the experiment, cells were incu-
bated with C12FDG (fluorogenic substrate, 5-dodecanoyl-aminofluorescein di-β-D-galactopyranoside; 33 µM, 
Invitrogen) at 37 °C for 30 min. The images (between 7–10 for each condition) were analyzed using Image 
Pro-Plus software (Media Cybernetic).
Western blot. Extracts from early passage and senescent endothelial cells, MVs from early passage and 
senescent HUVECs, as well as control and DFO-treated (100 µM, 8 hours, Sigma) senescent HUVECs were lysed 
in CytoBuster Protein Extraction Reagent lysis buffer (Millipore) containing protease and phosphatase inhib-
itor cocktail (Roche). The total protein content of lysates (cells and MVs) was quantified using a BCA Protein 
Assay Kit (Pierce), with BSA as the standard. Briefly, equal amounts of protein (10–70 μg protein/lane) were 
diluted with reducing sample buffer and separated by SDS/PAGE (7–10% gel) under reducing conditions. 
Samples were then transferred onto nitrocellulose membranes (BioRad), blocked with TBST (Tris-buffered 
saline, 0.1% Tween-20) containing 5% non-fat milk and then probed with the primary antibodies in the same 
buffer, at the following dilutions: Cyclin D1 (Thermo Scientific, Cat. No. RM-9104-SO, dilution 1/1000, 36 kDa), 
Lamin B1 (Abcam, ab133741, dilution 1/1000, 66 kDa), p53 (Cell Signaling Technology, #9282, dilution 1/1000, 
53 kDa), p16 (Abcam, ab51243, dilution 1/1000, 16 kDa), HIF1α (BD Transduction Laboratories, Cat No. 
610959, dilution 1/250, 120 kDa), Hsp90 (Cell Signaling, #4874, dilution 1/1000, 90 kDa); Anti-β-actin (Santa 
Cruz, sc-47778, dilution 1:2000, 43 kDa) and GAPDH (Millipore, Cat No. MAB374, dilution 1/2000, 38 kDa) 
were used as loading controls. After washing with TBST, the membranes were incubated with Novex horseradish 
Figure 10. Schematic representation of miR-126 and HIF-1α signaling pathway in replicative senescence 
model in vitro.
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peroxidase-conjugated secondary antibodies followed by 2 additional washing steps with TBST. Bands were vis-
ualized with Luminata Crescendo Western HRP substrate (Millipore). The quality of the proteins and the efficacy 
of protein transfer were evaluated by ATX Ponceau S red staining solution (Sigma; 09189). Finally, protein bands 
were quantified using Image J software (NIH) and normalized to β-actin or GAPDH in the HUVECs protein 
extracts and ATX Ponceau S red staining in the case of MVs. The HIF-1α protein blots were exposed for a long 
time (up to 30 min) to allow the detection of the absence/lack of expression of HIF-1α protein under some exper-
imental conditions.
Scratch assay. Culture-insert 2 well in µ-dish 35 mm was used to measure cell migration and cell prolifer-
ation rate (high ibiTreat, Ibidi). Each dish consists of two reservoirs separated by a 500 µm-thick wall. For the 
endothelial migration assay, an equal number of early passage and senescent endothelial cells were added into 
the two reservoirs of the same insert and incubated at 37 °C with 5% CO2. After 24 hours (when cultured cells 
reach 100% confluency), the insert was gently removed, creating a defined 500 µm cell-free gap. The well was filled 
with complete endothelial growth medium (EGM phenol red-free supplemented with growth bullet kit and 5% 
heat-inactivated FBS), and migration was observed using the Optika (Italy) microscope (magnification 100x). 
In addition, early passage endothelial cells were grown to confluency in culture-insert 2 well in µ-dish 35 mm, 
high ibiTreat (Ibidi) before wounding and exposed to DFO (100 µM) and different YC-1 concentrations for up 
to 8 hours. The wound pictures were captured by a digital camera at the same positions at 0, 1, 2, 3, 4, 5, 6, 7 and 
8 hours, after which wound area was determined using ImageJ software (NIH).
Endothelial tube formation assay. The 15 wells of a plate Ibidi μ-slide angiogenesis (Ibidi) were coated 
with factor-reduced Matrigel, according to the manufacturer’s instructions (Corning), and allowed to polymerize 
for 30 min at 37 °C. Early passage and senescent endothelial cells were seeded and grown in EGM phenol red-free 
supplemented with growth bullet kit and 5% heat-inactivated FBS for 6 hours in an incubator at 37 °C with 5% 
CO2. Also, early passage HUVECs (in 200 µL of EGM phenol red-free supplemented with growth bullet kit and 
5% heat-inactivated FBS) were seeded in each well in the absence (negative control) or presence of various YC-1 
concentrations for 6 hours in an incubator at 37 °C with 5% CO2 to form tubes. Network formation was observed 
and photographed using a phase-contrast inverted light microscope (Optika). Tube formation in the micropho-
tographs was quantitatively analyzed by measuring the number of tubes and nodes (branching points), and tube 
length were measured using NIH ImageJ software with the Angiogenesis Analyzer plugin. Tubular networks were 
stained using Calcein AM (BD Bioscience) to visualize the cells using fluorescence microscopy.
Real-time PCR. Total RNA was extracted from early passage and senescent HUVECs, as well as control 
and DFO-treated (100 µM, 8 hours) senescent HUVECs using the mirVana PARIS RNA and Native Protein 
Purification Kit (Ambion), according to the manufacturer’s instructions. cDNA was synthesized using the High 
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, California, USA) with 2 µg of total RNA primed 
with random hexamer primers, following the manufacturer’s instructions. Real-time polymerase chain reactions 
(PCR) were performed on ABI Prism 7500 sequence detection PCR system (TaqMan® Universal Master Mix 
II, No AmpErase® UNG; Applied Biosystems) according to the manufacturer’s protocol. Assay ID used was: 
HIF1-α, Hs00153153_m1. Data were normalized with HPRT1 (assay ID: Hs02800695_m1). The mRNA copy 
numbers were calculated for each sample by the instrument software using comparative threshold (Ct) value. 
Relative fold-change was determined using the 2−ΔΔCt method, with early passage HUVECs as the baseline 
and normalized to HPRT1 expression.
Real-time PCR of mature microRNAs. Total RNA was extracted from HUVECs, from MVs of early pas-
sage and senescent HUVECs, and from control and YC-1-treated early passage HUVECs. Total RNA was isolated 
using the mirVana PARIS RNA and Native Protein Purification Kit (Ambion) according to the manufacturer’s 
instructions. miRNA targets were reverse transcribed with a pool of the RT primers taken from TaqMan Small 
RNA Assays (Applied Biosystems) and total RNA using the TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems). A reaction master mix was assembled, spiked with reaction synthetic miR-39-3p (Ambion, 
ID: MC10956) and added to each RNA sample. Reaction tubes were kept on ice for at least 5 min, followed by 
incubation in a thermal cycler at 16 °C for 30 min, 42 °C for 30 min, 85 °C for 5 min, and kept at 4 °C. A micro-NTC 
(no-template control) that contained no sample RNA was included among these reverse-transcription reactions.
Subsequently, quantitative real-time PCR was performed in a PCR reaction containing 20x TaqMan miR 
Assay in which PCR primers and probes (5′-FAM) were contained, 2x TaqMan Universal Master mix no UNG 
(Applied Biosystems) and RT product. The reaction mix was first incubated at 95 °C for 10 min followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min. Assay ID used were: microRNA-126-3p, 002228: microRNA-126-5p, 
000451; U6 snRNA, 001973 and microRNA-39-3p, 000200, and were purchased by Applied Biosystems. The rela-
tive amount of each miRNA was calculated using the comparative threshold (Ct) method with ΔCt, Ct(miRNA)–
Ct(U6 snRNA) in endothelial cells and ΔCt, Ct(miRNA)–Ct(microRNA39-3p) in MVs. The miRs copy numbers 
were calculated for each sample by the instrument software using Ct value. Relative quantification of miRNA 
expression was calculated with the 2−ΔΔCt method, with early passage HUVECs as the baseline and normalized 
to U6 snRNA (internal control miRs) expression, and with early passage MVs as the baseline and normalized to 
microRNA39-3p exogenous sequence (spike-in) for MVs.
Cell transfection and miR-126 silencing. MiR-126 silencing in cultured cells was performed using either 
a predesigned mirVana miRNA inhibitor corresponding to the hsa-miR126-3p and hsa-miR-126-5p sequence 
(Assays ID: MH12841 and MH10401, respectively; Ambion) or an anti-miR negative control#1 (AM17012; 
Ambion). Transfections were performed on cells that were 80% confluent for 6 h with Lipofectamine RNAiMAX 
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reagent (Invitrogen) according to the manufacturer’s guidelines. Then, HUVECs were lysed after 72 hours of 
being transfected, and the lysate extraction was analyzed by Western blot.
Statistical analysis. Data are represented as the mean ± SD. Two groups comparison was calculated by 
the Student’s t-test (2-tailed p-values) or Mann-Whitney tests for the comparison of normally or not normally 
distributed variables, respectively. Otherwise, statistical significance was determined with ANOVA followed by 
the Kruskal-Wallis test. Values less than 0.05 were deemed to correspond to differences between means of two 
independent experiments that are statistically significant. P-value < 0.05 was considered as statistically significant 
wherein *p < 0.05, **p < 0.01 and ***p < 0.001. GraphPad Prism 6 was used to determine statistical significance.
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